By a News Reporter-Staff News Editor at Clinical Oncology Week -- Investigators discuss new findings in Oncology. According to news reporting originating in Chicago, Illinois, by NewsRx journalists, research stated, "Glioblastoma-targeted drug delivery systems facilitate efficient delivery of chemotherapeutic agents to malignant gliomas, while minimizing systemic toxicity and side effects. Taking advantage of the fibrin deposition that is characteristic of tumors, we constructed spherical, Cy7-labeled, targeting micelles to glioblastoma through the addition of the fibrin-binding pentapeptide, cysteine-arginine-glutamic acid-lysine-alanine, or CREKA."
The news reporters obtained a quote from the research from the University of Chicago, "Conjugation of the CREKA peptide to Cy7-micelles increased the average particle size and zeta potential. Upon intravenous administration to GL261 glioma bearing mice, Cy7-micelles passively accumulated at the brain tumor site via the enhanced permeability and retention (EPR) effect, and Cy7-CREKA-micelles displayed enhanced tumor homing via active targeting as early as 1 h after administration, as confirmed via in vivo and ex vivo imaging and immunohistochemistry. Biodistribution of micelles showed an accumulation within the liver and kidneys, leading to micelle elimination via renal clearance and the reticuloendothelial system (RES). Histological evaluation showed no signs of cytotoxicity or tissue damage, confirming the safety and utility of this nanoparticle system for delivery to glioblastoma."
According to the news reporters, the research concluded: "Our findings offer strong evidence for the glioblastoma-targeting potential of CREKA-micelles and provide the foundation for CREKA-mediated, targeted therapy of glioma."
For more information on this research see: Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials, 2014;35(4):1249-56. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news correspondents report that additional information may be obtained by contacting E.J. Chung, Institute for Molecular Engineering, The University of Chicago, 5747 S Ellis Ave Jones 222, Chicago, IL 60637, United States. Additional authors for this research include Y. Cheng, R. Morshed, K. Nord, Y. Han, M.L. Wegscheid, B. Auffinger, D.A. Wainwright, M.S. Lesniak and M.V Tirrell (see also Oncology).
Keywords for this news article include: Chicago, Illinois, Oncology, Glioblastoma, United States, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC